BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32268011)

  • 1. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 4. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
    Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
    Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
    Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
    Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression patterns of immune checkpoints in acute myeloid leukemia.
    Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
    J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
    Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
    Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
    Pittet CL; Newcombe J; Prat A; Arbour N
    J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased exhausted CD8
    Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequencies of PD-1- and PD-L1- positive T CD3
    Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
    Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface.
    Meggyes M; Miko E; Szigeti B; Farkas N; Szereday L
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):74. PubMed ID: 30782114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High programmed death 1 expression on T cells in aplastic anemia.
    Zhao W; Zhang Y; Zhang P; Yang J; Zhang L; He A; Zhang W; Hideto T
    Immunol Lett; 2017 Mar; 183():44-51. PubMed ID: 28153603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.
    Jalali S; Price-Troska T; Paludo J; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Ansell SM
    Blood Adv; 2018 Aug; 2(15):1985-1997. PubMed ID: 30104397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.
    Wilson JK; Zhao Y; Singer M; Spencer J; Shankar-Hari M
    Crit Care; 2018 Apr; 22(1):95. PubMed ID: 29661225
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Vos L; Dietrich J; Strieth S; Bootz F; Dietrich D; Franzen A
    Immunotherapy; 2020 Aug; 12(12):903-920. PubMed ID: 32684057
    [No Abstract]   [Full Text] [Related]  

  • 19. Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
    Van den Bergh JMJ; Smits ELJM; Berneman ZN; Hutten TJA; De Reu H; Van Tendeloo VFI; Dolstra H; Lion E; Hobo W
    Cancer Immunol Res; 2017 Aug; 5(8):710-715. PubMed ID: 28637876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.